特罗凯?对各种类别非小细胞肺癌患者均有效3，5
Tarceva? showed beneficial effect in all types of NSCLC 3，5
对所有NSCLC患者人群都有生存优势的靶向药物
The target drug providing survival advantage in all NSCLC patient groups.
NSCLC患者群中，ECOG PS≤2的患者特罗凯?与二线化疗结果相媲美，针对ECOG PS 3的患者特罗凯?治疗有效
Among groups of NSCLC patients, result of Tarceva? therapy is comparable to those of second-line chemotherapy regimen in patients with ECOG PS≤2. Tarceva? therapy also provided beneficial effect in patients with ECOG PS 3.
华译网上海翻译公司曾经翻译过大量有关肿瘤细胞的资料文件，Beijing Chinese Subtitling Translation Service Agency has translated many technical documents about Tumor cell.
特罗凯?关键性III临床试验2.3.6 化疗III期临床试验
Tarceva? key phase III clinical trial2.3.6 Chemotherapy phase III clinical trial
患者资料 特罗凯? BSC 培美曲塞 多西紫杉醇6，7 多西紫杉醇 vs. BSC
Characteristics Tarceva? BSC pemetrexed taxotere 6，7 taxotere vs. BSC
(既往化疗方案1个，PS评分0-1分患者)
(Patients receiving one prior chemotherapy regimen with PS 0-1)
注：ECOG PS 美国肿瘤协作针对癌症患者功能状态评分，评分越高，身体状况越差
Note: ECOG PS: Eastern Cooperative Oncology Group performance status. Higher score means worse performance status.
* 患者具有可测量病灶
* Patients had measurable disease.
全面提高患者生活质量 服用方便，耐受性理想
Broadly improvement of patients’ life of quality Taken conveniently Ideal tolerance
特罗凯?耐受性好，无化疗的白细胞减少和粒细胞缺乏的不良反应3，9
Tarceva? is well tolerated without leucopenia or agranulocytosis as adverse effect of chemotherapy.
多西紫杉醇 特罗凯?
Doxotere Tarceva?
中性粒细胞减少
Leucopenia
皮疹的程度与生存期密切相关10
The degree of rash is closely correlated with survival
生存率
Survival rate
对所有NSCLC患者人群都有生存优势的靶向药物
The target drug providing survival advantage in all NSCLC patient groups.
特罗凯?Tarceva?显著延长非小细胞肺癌患者生存
Tarceva? significantly prolonged survival in patients with NSCLC
特罗凯?Tarceva?显著延长生存期，改善患者生活质量
Tarceva? significantly prolonged survival and improved patients’ quality of life.
特罗凯?Tarceva?显著延长总体生存期1，2
Tarceva? remarkably prolonged overall survival.
生存概率（%）
Survival rate(%)
特罗凯?Tarceva?对各种类别非小细胞肺癌患者均有效1
Tarceva? showed beneficial effect in all types of NSCLC 3，5
特罗凯?Tarceva?耐受性好，无骨髓抑制和神经毒性1
Tarceva? is well tolerated without bone marrow suppression or nerve toxicity
PS2-3患者对特罗凯?Tarceva?也能很好耐受
Tarceva? is also well tolerated in patients with PS 2-3
特罗凯?Tarceva?唯一被证实对晚期非小细胞肺癌具有生存优势的HER1/EGFR酪氨酸激酶抑制剂1
Tarceva? is the only HER1/EGFR tyrosin kinase inhibitor which is proved to provide survival benefit in advanced NSCLC.
更高的血药浓度，更强的抑制磷酸化活性3，4，5
Higher blood drug concentration, Stronger inhibition of phosphorylation3，4，5
特罗凯?Tarceva?
Tarceva?
增强化疗敏感度
Improvement of chemotherapy sensitivity
抑制新生血管形成
Inhibition of angiogenesis
促进肿瘤细胞凋亡
Enhancement of tumor cell apoptosis
降低肿瘤细胞粘附能力
Reduction of tumor cell adhesion
抑制肿瘤细胞增殖、侵袭、转移
Inhibition of tumor cell proliferation, invasion and metastasis
更多的临床获益，源于其卓越的药代动力学3，4，5，8
Excellent pharmacokinetic characteristic results in more clinical benefit
体内/外活性高：IC50分别为2nM/16-20nM
High activity in vivo/vitro : IC50 is 2nM/16-20nM separately
极少量的特罗凯?Tarceva?就可以显著抑制EGFR酪氨酸激酶活性
An extreme low dose of Tarceva? can remarkably inhibit activity of EGFR tyrosine kinase.
药物暴露浓度高：150mg AUC =
High concentration of drug exposure: 150mg AUC = 16,500ng?h/L
药物抗肿瘤作用与AUC呈正相关，浓度越高，抗肿瘤活性越强
Antitumor activity of drug is positively correlated with AUC. Higher concentration leads to more powerful antitumor activity.
半衰期 T1/2 = 18小时
Half-life time T1/2 = 18 hours
特罗凯?Tarceva?每日一次给药不会引起药物体内蓄积从而导致不良反应的增加
Daily dosing of Tarceva? doesn’t result in drug accumulation which leads to an increase of adverse effect
最大耐受剂量：MTD = 150mg
Maximum tolerance dose: MTD = 150mg
在患者耐受的基础上，使用最大耐受剂量可发挥最佳疗效
Based on tolerance of the patients, MTD provides best beneficial effect |
